Inogen Inc (INGN) · Nov 19, 2026 · Exec change

Inogen CEO separation adds $1.47M severance as turnaround resets

CEO separation — $1.47M salary severance over 24 months; up to $610,026 target bonus

Inogen’s CEO separation agreement discloses $1.47 million in salary severance, a potential 2026 bonus, and limited equity acceleration.

Inogen is in the middle of a reset: it has exited its U.S. oxygen-rental business, launched a $20 million cost-reduction program, and is refocusing on respiratory-device sales and profitable growth under new CEO Andy Reding. The CEO transition itself was already disclosed on November 5, so this filing is mainly the financial and legal settlement behind Kevin Smith’s October 30 departure.

The filing puts a meaningful price tag on the leadership change. Inogen will pay Smith $1.4697 million over 24 months, continue certain health benefits, and leave him eligible for a performance-based 2026 bonus with a $610,026.16 target. 〔0〕 〔1〕

Compensation itemAmount / dateComparison
Salary severance (Consideration)$1.4697M24 months
Monthly severance (Consideration)$61,237.5024 payments
2026 bonus target (Consideration)$610,026.16Payable by Mar. 15, 2027
Equity acceleration (Equity Acceleration)Scheduled Dec. 1, 2026 vestingSettles Dec. 1, 2026
Separation date (Recitals)Oct. 30, 2026—

The agreement also closes the door on future claims and ongoing company roles. Smith resigns from all officer, employee, and director positions, forfeits unvested equity except for awards scheduled to vest on December 1, and releases broad employment-related claims. 〔2〕 〔3〕 〔4〕

Relative to expectations, this is more detail than surprise. The departure and planned separation agreement were already announced, so the filing does not change who is running Inogen or its strategic direction. The new information is the sizable but contractual payout, which modestly adds to the cost of a transition already embedded in the company’s turnaround plan; the agreement also states Smith’s resignation was not due to disagreement with company operations or policies. 〔5〕

Bottom line: This filing formalizes an already-known CEO change and quantifies its cost rather than rewriting Inogen’s business story. It is modestly negative for the company because of the cash and compensation burden, but the main transition was already public and the agreement removes some uncertainty around the exit.

What to watch next

2027 annual meeting and continued turnaround execution

Original filing on SEC EDGAR

More Inogen Inc news

Inogen CEO separation adds $1.47M severance as turnaround resets | INGN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.